国际眼科杂志2016，Vol.16Issue(5)：905-908,4.DOI:10.3980/j.issn.1672-5123.2016.5.28
病理性近视脉络膜新生血管抗 VEGF治疗期间黄斑中心凹下的脉络膜厚度变化
Changes of subfoveal choroidal thickness after treated by Ranibizumab for choroidal neovascularization secondary to pathologic myopia
摘要
Abstract
AlM:To observe the change of subfoveal choroidal thickness ( SFCT ) after intravitreal injections of anti -vascular endothelial growth factor monoclonal antibody Ranibizumab in patients with choroidal neovascularization ( CNV ) secondary to pathologic myopia ( PM ) and to research the relation between visual acuity and SFCT. <br> METHODS:This was a prospective, contrast, open-label study. Fifty pathologic myopia patients with CNV (50 eyes) were recruited in this study. Before the injection, best-corrected visual acuity detected by visual chart from Early Treatment of Diabetic Retinopathy Study ( ETDRS ) , non - contact tonometer, ophthalmoscope, fundus photography, fundus fluorescein angiograph ( FFA ) and optical coherence tomography ( OCT ) examination were necessary. All affected eye were treated with intravitreal ranibizumab 0. 05mL. Following up for 12mo, the changes of visual acuity and SFCT were compared before and after treatment, also the relation between them. <br> RESULTS:All eyes received an average of 2. 47 ± 2. 23 injections,the final vision of follow-up increased by 13. 62± 8.98 letters than that before(t=6.69,P<0.05). The SFCT before therapy, 1, 6 and 12mo after treatment were 81. 48± 61.62, 79.63±60.98, 77.92±61.26 and 78.34±59.48μm and respectively decreased by 2. 09 ± 8. 93, 3. 68 ± 7. 42, 3. 16 ± 6. 95μm compare to pre- treatment. The difference on SFCT at 1mo was not significant compared to before treatment(t=0. 95, P>0. 05). While after 6 and 12mo,the differences were significant ( t = 2. 34, 2. 61;P<0. 05 ). Twenty-four eyes ( 48%) were with recurrence, mean recurrence times were 1. 39 ± 1. 23. The SFCT increased from 75. 7 ± 51. 6μm at 1mo to 84. 4 ± 55. 9μm ( by 11. 5%) when recurred, there were significant differences ( P <0. 05). Twenty-six eyes (52%) were not with recurrence. The SFCT at 1, 6 and 12mo after treatment were 85. 3 ± 52. 7, 83. 6 ± 50. 5 and 84. 2 ± 54. 2μm, there were no significant differences with multiple comparison(P>0. 05). There were no serious systemic or local side effects during the follow up. <br> CONCLUSlON: lntravitreal ranibizumab for CNV secondary to pathologic myopia is safe and can improve the visual acuity. lntravitreal injections of ranibizumab can induce SFCT reduction for CNV secondary to pathologic myopia. We hypothesized that increase of SFCT may be one of evaluation index for CNV activity.关键词
病理性近视/雷珠单抗/CNV/中心凹下脉络膜厚度/光学相干断层扫描/早期治疗研究Key words
pathologic myopia/ranibizumab/choroidal neovascularization/subfoveal choroidal thickness/optical coherence tomography/Early Treatment of Diabetic Retinopathy Study引用本文复制引用
袁建树,吴越,王育文..病理性近视脉络膜新生血管抗 VEGF治疗期间黄斑中心凹下的脉络膜厚度变化[J].国际眼科杂志,2016,16(5):905-908,4.基金项目
浙江省卫生厅医药卫生一般研究计划( No.2013KYA186)@@@@Medical and Health Research Project frol Public Health Departlent of Zhejiang Province(No.2013KYA186) （ No.2013KYA186）
